retatrutide clinical trials weight loss retatrutide Phase 3: 60% Achieved Surgical-Level The retatrutide drug is manufactured

Slower digestion, reduced fluid intake, and changes in gut movement all work together to increase the risk of constipation

adults going around 40% during August 2021 to August 2023

The new label includes references to some of those postmarketing risks, including intestinal obstruction, [and] severe constipation including fecal impaction. Some patients who took Zepbound have filed lawsuits, accusing Eli Lilly of failing to properly warn them that Zepbound could increase their risk of severe gut problems, including bowel obstructions, pancreatitis, and gastroparesis

If youre calling on behalf of someone else, stay with them until help arrives

Clinical guidance on switching protocols will emerge post-approval

In all other patients with type 2 diabetes (i.e